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Bevirimat (BVM; formerly known as PA-457) is a novel inhibitor of human immunodeficiency virus (HIV)
maturation that is being developed for the treatment of HIV infection. The pharmacokinetics of this agent in
healthy male volunteers were studied in a randomized, double-blind study in which the participants received
single oral doses of placebo (n  8) or escalating doses of BVM at 25, 50, 100, or 250 mg (n  6 per dose);
escalation was performed only after the pharmacokinetics and safety of the preceding dose had been evaluated.
Plasma was collected over 480 h after dosing and urine was collected over 48 h after dosing for determination
of the values of pharmacokinetic parameters. BVM was well absorbed after oral administration, with peak
plasma concentrations being achieved 1 to 3 h after dosing. The half-life was 60 to 80 h. The exposure assessed
by determination of the peak concentration and the area under the concentration-time curve was dose
proportional. Single oral doses of BVM were well tolerated: there were no dose-limiting toxicities, and no
serious adverse events were reported. These findings suggest that that BVM offers a favorable pharmacokinetic
profile, with predictable pharmacokinetics following the oral administration of single doses. The long half-life
of BVM may facilitate once-daily dosing.
Although the introduction of highly active antiretroviral
therapy regimens has significantly improved the prognosis for
people infected with human immunodeficiency virus (HIV)
type 1 (HIV-1) (2, 9), the development of viral resistance
presents a major clinical challenge. It is estimated that up to
78% of individuals with HIV-1 infection harbor drug-resistant
strains (10) and that 5 to 10% of strains are resistant to all
classes of reverse transcriptase and viral protease inhibitors
(4). The growing problem of resistance necessitates the devel-
opment of new agents and regimens for the control of HIV
infection (1). One response to this need has been to investigate
therapeutic targets other than reverse transcriptase and viral
protease, which have traditionally been the targets of highly
active antiretroviral therapy regimens.
Bevirimat (BVM; formerly known as PA-457) [3-O-(3,3-
dimethylsuccinyl)betulinic acid] (Fig. 1) is the first of a new
class of antiretroviral agents that inhibit HIV-1 replication by
disrupting virus maturation. BVM inhibits the final step in the
Gag processing cascade, resulting in defective core condensa-
tion and the release of noninfectious virus particles from HIV-
1-infected cells, thus blocking the spread of the infection to
new cells (5). Due to this novel mechanism of action, BVM
shows potent activity against HIV-1 strains that are resistant to
all currently approved classes of antiretroviral agent (3).
In vitro studies have shown that BVM does not undergo
oxidative metabolism in human microsomes, does not inhibit
the cytochrome P450 system, and does not interact with human
Pgp (6). It is a substrate for UDP-glucuronosyltransferases,
and since it contains two carboxylic acid moieties and no other
functional groups that are commonly conjugated with glucu-
ronic acid, it is likely that the formation of acyl glucuronide
metabolites may contribute to its elimination (13). This may
result in a more favorable safety profile, with less potential for
drug interactions, than those of existing antiretroviral thera-
pies. This paper describes the first study of the safety, tolera-
bility, and pharmacokinetics of BVM in healthy volunteers.
MATERIALS AND METHODS
The study was a double-blind, randomized, placebo-controlled, parallel-group,
dose-escalation study conducted at a single center in the United States. It was
conducted according to the principles of the Declaration of Helsinki and Good
Clinical Practice, and the protocol was approved by the Integreview Ethical
Review Board (Austin, TX).
Participants. Male volunteers (age range, 18 to 55 years) of any race were
eligible to participate in the study. Participants were required to have a body
mass index (BMI) of between 18.5 and 30 kg/m2 and to be in good health, as
judged by medical history, physical examination, and clinical laboratory evalua-
tion. Participants with clinically significant medical or psychiatric conditions or
abnormal laboratory test results were excluded from the study, as were those with
a history of excessive alcohol consumption or drug abuse or who tested positive
for hepatitis virus or HIV infection. Written informed consent was obtained from
all participants prior to inclusion in the study.
Treatment. Participants were randomized in a 2:6 ratio to receive placebo or
single oral doses of BVM. BVM was given as a solution containing the di-N-
methylglucamine salt in escalating doses equivalent to 25, 50, 100, and 250 mg of
the free acid. The investigators were blinded to the treatment allocation (BVM
or placebo) but not to the dose of BVM; doses were escalated for successive
cohorts of eight participants only after the safety and pharmacokinetic data for
the previous dose had been evaluated. Each dose was given, after an overnight
fast of at least 8 h, as 60 ml of the oral solution, and the dosing vessel was rinsed
three times with 60 ml tap water, which was consumed by the participant. A
standardized meal (150 protein calories, 250 carbohydrate calories, and
500 to 600 fat calories) was provided 4 h after dosing. Alcohol-, caffeine-, and
xanthine-containing foods or beverages were prohibited from 24 h before to 48 h
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after dosing. Grapefruit and grapefruit-containing juices were prohibited from 1
week before dosing until the completion of the study. The participants were
asked to refrain from excessive physical exercise or contact sports during the
same period. The use of any unauthorized prescription or over-the-counter
medication was prohibited from 14 days prior to dosing until the completion of
the study, although the participants could take acetaminophen up to 48 h before
dosing. The participants were also asked to avoid the use of drugs known to
inhibit or induce hepatic drug metabolism from 30 days prior to dosing. The
study participants remained in the dosing unit for 48 h after dose administration
and were then required to report back for blood sampling during the remainder
of the study.
Pharmacokinetic analysis. Blood samples (10 ml) were obtained via an in-
dwelling catheter or by venipuncture prior to dosing and at 0.25, 0.5, 0.75, 1, 1.5,
2, 3, 4, 6, 8, 10, 12, 18, 24, 30, 36, 42, 48, 96, 144, 192, 240, 288, 336, 384, 432, and
480 h after dosing (or at times within 10% of those time points after 48 h).
Samples were collected into heparinized tubes, and plasma was separated within
30 min of collection by centrifugation at 1,500  g for 10 min at 4°C. Duplicate
plasma samples were stored at 70°C prior to analysis.
Urine was collected over time periods of approximately 0 to 12, 12 to 24, 24 to
36, and 36 to 48 h after dosing. The urine volume and the creatinine concentra-
tion were measured, and duplicate 20-ml samples were stored at 70°C.
The concentrations of BVM in plasma and urine were measured by means of
validated high-performance liquid chromatography assays with tandem mass
spectrometric detection. The internal standard was 2,2-dimethylsuccinyl-4-dihy-
drobetulinic acid ester (DSD). The precursor/fragment ions of BVM were
583.53455.4 m/z in heparinized plasma and acidified urine and 583.33455.2 m/z
in acidified plasma; the precursor/fragment ions of DSD were 585.33457.3 m/z
for both plasma and urine samples. The assays were validated over the range 0.02
to 60.0 g/ml (plasma) and 100 to 40,000 ng/ml (urine). The accuracy and
precision (measured as the relative standard deviation) ranged from 96.3 to
105% and 5.5 to 9.6%, respectively, in plasma and from 83.7 to 94.2% and 3.8 to
10.3%, respectively, in urine.
Since acyl glucuronides can be unstable at neutral pH (11), one plasma sample
from each pair of duplicates from the participants receiving the highest dose of
BVM was acidified to pH 3 to 4 by the addition of glacial acetic acid in order to
stabilize any putative glucuronide conjugates of BVM. These samples were then
assayed with and without enzymatic hydrolysis with -glucuronidase for 18 h at
37°C. The concentrations of conjugated BVM were calculated as the differences
in the concentrations between the hydrolyzed and the nonhydrolyzed samples.
The BVM concentrations measured in acidified and hydrolyzed samples were
not significantly different from those measured in acidified and nonhydrolyzed
samples or nonacidified and nonhydrolyzed samples. This shows that the circu-
lating concentrations of BVM conjugates are very low and that analysis of
nonacidified, nonhydrolyzed samples accurately measures plasma BVM concen-
trations. Hence, all concentrations presented in this paper represent those of the
free acid of BVM.
The concentrations of BVM conjugates in urine were measured as the differ-
ence between the concentrations in acidified samples with and without enzymatic
hydrolysis (-glucuronidase, 4 h at 37°C).
The values of the pharmacokinetic parameters of BVM in plasma were esti-
mated by noncompartmental methods. Maximum concentrations in plasma
(Cmaxs) and the times to the Cmaxs (Tmaxs) were derived directly from concen-
tration-time plots. The following pharmacokinetic parameters were estimated:
the area under the concentration-time curve (AUC) to the time of the last
quantifiable concentration, the AUC extrapolated to infinity (AUC0–), the
elimination rate constant (	z; determined by linear regression analysis of the
terminal points of the log-linear plasma concentration-time curve), the terminal
half-life [t1/2; determined as ln(2)	z]), and the apparent oral clearance (CL/F;
calculated as the dose divided by AUC0–). The amount of BVM excreted in the
urine was calculated from the urine data.
Safety analyses. Safety was assessed by monitoring the participants for adverse
events throughout the study. In addition, a physical examination was performed
at the beginning of the study and at follow-up 21 days after dosing; and vital signs
were measured and an electrocardiogram (ECG) and clinical laboratory test-
ing were performed prior to dosing, at various times during the study, and at
follow-up.
Statistics. Statistical analysis was performed by using the SAS System for
Windows (version 8.2; SAS Institute Inc., Cary, NC). For the pharmacokinetic
analyses, plasma concentrations and pharmacokinetic parameters were summa-
rized by dose and treatment by using descriptive statistics; missing data were
omitted from these calculations. Dose proportionality was assessed by means of
the following power model: log(parameter) 
 a  b  log(dose), where a is the
intercept and b is the slope. Dose proportionality was assumed if the 95%
confidence intervals for the estimate of the slope included 1.0. A two-tailed
probability of 0.05 or less was regarded as statistically significant. Demographic
and baseline characteristics were summarized by using descriptive statistics for
continuous variables and frequency distributions for discrete variables.
Due to the variation in sampling times between 48 and 480 h (after the
participants left the clinical study unit), group mean and median pharmacoki-
netic variables could not be calculated for discrete time points after 48 h. The
pharmacokinetic parameters for individuals during the elimination phase were
calculated on the basis of individual data, and summary statistics were calculated
to describe the results by dose group.
All safety data were summarized by dose level. Descriptive statistics and the
mean change from the baseline were determined for clinical laboratory tests,
vital signs, and ECG variables.
RESULTS
A total of 32 volunteers were enrolled, all of whom com-
pleted the study. Eight participants received placebo, and 24
(six per dose level) received BVM. The demographic charac-
teristics of the participants are summarized in Table 1.
Pharmacokinetics. There were no significant differences be-
tween the mean BVM concentrations obtained from acidified
plasma samples (hydrolyzed and nonhydrolyzed) and nonacidi-
fied plasma samples. Thus, the amount of circulating BVM
FIG. 1. Structure of BVM [3-O-(3,3-dimethylsuccinyl)betulinic
acid].
TABLE 1. Baseline demographic characteristics
Treatment
group (n)
Mean age  SD
(yr), range
Race (no. [%] African/
Caucasian/Hispanic)
Mean ht  SD
(cm), range
Mean wt  SD
(kg), range
Mean BMI  SD
(kg/m2), range
Placebo (8) 30.4  8.9 (20–46) 4/4/0 (50/50/0) 181.3  6.9 (170.2–193.0) 89.3  16.0 (59.1–108.6) 27.0  3.7 (19.2–30.0)
BVM, 25 mg (6) 33.3  11.0 (18–46) 3/2/1 (50/33/16.7) 176.1  8.5 (165.1–188.0) 87.0  10.2 (69.1–99.5) 28.1  2.7 (24.1–30.0)
BVM, 50 mg (6) 29.5  14.6 (19–54) 0/5/1 (0/83.3/16.7) 174.8  6.5 (170.2–185.4) 84.1  7.0 (78.6–95.0) 27.6  2.6 (22.9–30.2)
BVM, 100 mg (6) 31.0  12.9 (20–49) 1/5/0 (16.7/83.3/0) 177.0  8.3 (162.6–185.4) 77.7  10.6 (60.9–91.4) 24.8  3.0 (21.7–28.9)
BVM, 250 mg (6) 33.8  9.2 (20–43) 3/3/0 (50/50/0) 174.8  5.7 (167.6–182.9) 77.8  13.5 (64.1–96.4) 25.3  3.8 (20.3–30.5)
Total (32) 31.5  10.7 (18–54) 11/19/2 (34.4/59.4/6.3) 177.1  7.2 (162.6–193.0) 83.5  12.4 (59.1–108.6) 26.6  3.3 (19.2–30.5)
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glucuronides was low or nonexistent, and analysis of nonacidi-
fied plasma samples was used to quantitate BVM.
BVM was rapidly absorbed after oral administration: in all
participants, detectable concentrations were present in the
plasma within 15 min after administration and peak concen-
trations were reached within 1 to 3 h. The mean concentration-
time profiles to 48 h for the four doses of BVM are shown in
Fig. 2; the exact timing of collection of the samples obtained
after 48 h varied between participants (but were within 10% of
the specified dosing interval) and therefore are not summa-
rized with descriptive statistics. Data for up to at least 336 h
were available for 19 of 24 of the study participants, and data
for the full 480-h period were available for 12 of 24 subjects.
All participants had measurable concentrations of BVM in
their final sample, and the observed data represented more
than 97% of the AUC0– values for all participants. Inspection
of the individual concentration-time profiles for each partici-
pant did not reveal any secondary peaks of BVM that would be
consistent with the enterohepatic circulation of glucuronide
conjugates; Fig. 3 shows the concentration-time profiles for the
duration of the study for participants who received the 250-mg
dose as examples of the individual plots obtained.
The values of the pharmacokinetic parameters for BVM in
plasma are summarized in Table 2. The median Tmax ranged
from 1.0 to 2.5 h across the dose groups. The mean t1/2 ranged
from 58 to 80 h, and the mean CL/F ranged from 1.55 to 2.11
ml/h/kg.
Due to the variability in subject body weight within and
across cohorts, Cmax and AUC0– were normalized to a body
weight of 70 kg to assess the relationship between dose and
exposure (Table 2). Doubling of the dose from 25 mg to 50 mg
resulted in an approximately 2.2-fold increase in the mean
normalized AUC0– and a 2.6-fold increase in the mean nor-
malized Cmax, while a 4-fold increase in dose from 25 mg to 100
mg resulted in an approximately 5.5-fold increase in the mean
normalized AUC0– and Cmax, and a 10-fold increase in dose
from 25 mg to 250 mg resulted in an approximately 12-fold
increase in the mean normalized AUC0– and Cmax. The linear
test for dose proportionality showed that increases in the nor-
malized Cmax (mean  standard error slope, 1.07  0.05 g/
ml; 95% confidence interval 
 0.95, 1.18) and AUC0–
(mean  standard error slope, 1.10  0.06 g  h/ml; 95%
confidence interval 
 0.98, 1.22) were dose proportional.
The measurement of unconjugated and conjugated BVM in
urine samples from subjects in the highest-dose group (250
mg) accounted for approximately 0.82% of the administered
dose with collections to 48 h. As a result, no formal estimation
of renal clearance was done.
Safety and tolerability. All doses of BVM were well toler-
ated. A total of 18 treatment-emergent adverse events were
reported by seven participants receiving BVM (29.2%) and
four placebo-treated participants (50%); within the BVM
groups, the numbers of participants reporting treatment-emer-
gent adverse events were one each (16.7%) with the 25- and
50-mg doses, three (50%) with the 100-mg dose, and two
(33.3%) with the 250-mg dose. Headache was the most fre-
quently reported adverse event, being reported by four partic-
ipants receiving BVM and one participant receiving placebo,
followed by pharyngitis in two participants receiving BVM. All
adverse events were mild in severity. No serious adverse events
were reported, and no participants discontinued taking the
study drug due to adverse events. Six adverse events (33.3%)
were considered drug related. There were sporadic elevations
in clinical laboratory variables, but none of the abnormal lab-
oratory values were considered clinically significant and none
were reported to be adverse events. There were no clinically
relevant changes in vital signs, ECGs, or physical examinations.
DISCUSSION
This study showed that the oral administration of BVM in
humans resulted in plasma levels that increased with dose.
Exposure to BVM based on Cmax and AUC was dose propor-
tional across all doses studied. The protein binding-adjusted
90% inhibitory concentration of BVM is 2.3 g/ml (7), and
the Cmaxs of the two higher doses studied exceeded this value
for at least 48 h following dose administration.
Compliance with complicated multidrug antiviral regimens
is a major issue in the successful treatment of HIV. Effective
FIG. 2. Mean plasma concentration-time profiles (standard devi-
ation) to 48 h following the administration of single oral doses of BVM
at 25, 50, 100, and 250 mg.
FIG. 3. Concentration-time profiles for participants who received
BVM at 250 mg.
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antiviral medications that can be administered once daily
should result in increased compliance, an enhanced quality of
life, and improved treatment outcomes. The long t1/2 observed
following oral dosing makes BVM a potential candidate for
once-daily dosing. This long t1/2 suggests that accumulation in
the range of three- to fivefold is likely to occur during regular
dosing (7, 12) and is consistent with the extensive protein
binding of BVM in plasma. Plasma protein binding is also
compatible with the low levels of glucuronidation and urinary
excretion of BVM observed in this study.
BVM was well tolerated by the subjects in all dose groups
when it was administered as single oral doses. There were no
dose-limiting toxicities, and no serious adverse events were
reported. No clinically relevant findings in clinical laboratory
values, vital signs, ECGs, or physical examinations were noted
during the study.
The safety profile and potential for drug interactions are also
important aspects of multidrug antiviral regimens. In vitro
studies have shown that BVM does not undergo oxidative
metabolism in human liver microsomes, does not inhibit the
cytochrome P450 system, and does not interact with human
Pgp (6). BVM has been shown to be glucuronidated in the rat
(9), and hence, one objective of this study was to determine the
concentrations of putative BVM glucuronides in human
plasma and urine following oral dosing. The results showed
that the levels of glucuronidated BVM in plasma are either
extremely low or nonexistent in humans. A small fraction of
the dose (less than 1%) was measurable in urine as putative
BVM glucuronides, whereas unconjugated BVM was unmea-
surable in urine; thus, renal clearance appears to be insignifi-
cant for the elimination of single doses of BVM. BVM glucu-
ronides may be excreted in bile, but further in vivo studies are
required to fully define the metabolism and excretion of BVM.
In summary, the pharmacokinetics of BVM following the
oral administration of single doses are predictable in healthy
volunteers, and its long t1/2 may support once-daily dosing (8).
The good safety profile of BVM seen after the administration
of single oral doses is also encouraging. These issues are im-
portant when drugs are selected for inclusion in multidrug
antiviral regimens for the treatment of HIV infection, and
these data warrant further investigation of BVM in patients
with HIV infection.
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TABLE 2. Pharmacokinetic parameters of BVM in plasmaa
Dose AUC0– (g  h/ml)b
AUC0– (g  h/ml)
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Cmax (g/ml)
(normalized)c Tmax (h) t1/2 (h) CL/F (ml/h/kg)
25 151.2 (102.5–190.2) 170.2 (127.0–223.8) 2.24 (1.75–3.02) 2.8 (2.1–3.9) 1.75 (1.0–3.0) 55.82 (49.74–72.27) 173.36 (135.64–251.72)
50 312.1 (258.6–443.4) 362.1 (281.3–552.5) 6.06 (5.68–7.21) 7.3 (6.2–7.9) 1.0 (1.0–2.0) 56.69 (50.33–85.66) 165.34 (116.36–199.57)
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250 1,795.7 (1,433.9–2,793.2) 2,221.8 (1,556.3–2,513.0) 30.05 (25.50–38.40) 31.1 (27.1–44.2) 2.5 (1.0–3.0) 69.00 (54.29–82.46) 145.68 (93.66–182.44)
a Data are presented as median (range); n 
 6 for all dosage groups.
b Percentage of AUC extrapolated to infinity was 3% in all participants.
c Adjusted for the target dose in a 70-kg subject.
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